Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the interest coverage ratio high or low?
The interest coverage ratio of -30.90x is 22% below its 3-year average of -25.29x, around the middle of its 3-year range (-47.80x–-13.47x).
17.32% above its 12-month average of -37.37x.
Reported quarterly interest coverage; no daily interpolation. Q2 FY2026 (2026-06-30): -45.62x.
INTEREST COVERAGE RATIO
-30.90x
INTEREST COVERAGE RATIO AVG TTM
-37.37x
INTEREST COVERAGE RATIO AVG 3Y
-26.17x
INTEREST COVERAGE RATIO AVG 5Y
N/A
INTEREST COVERAGE RATIO AVG 10Y
N/A
INTEREST COVERAGE RATIO AVG 15Y
N/A
INTEREST COVERAGE RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
+17.32%
CURRENT VS 3Y AVG
-18.06%
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-2.24x
median of 262 covered companies
CURRENT VS SECTOR MEDIAN
-1279.46%
vs the sector median at left
CeriBell, Inc.
Market Cap
$943.26M
Interest Coverage Ratio
-30.90x
TTM Avg
-37.37x
3Y Avg
-26.17x
5Y Avg
N/A
Market Cap
$922.50M
Interest Coverage Ratio
-278.88x
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$915.95M
Interest Coverage Ratio
2.21x
TTM Avg
2.21x
3Y Avg
2.21x
5Y Avg
5.08x
Market Cap
$903.13M
Interest Coverage Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$985.79M
Interest Coverage Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$989.05M
Interest Coverage Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$867.60M
Interest Coverage Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$852.55M
Interest Coverage Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | INTEREST COVERAGE RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| CeriBell, Inc. (CBLL) | $943.26M | -30.90x | -37.37x | -26.17x | N/A |
| Arbutus Biopharma Corp (ABUS)vs › | $922.50M | -278.88x | N/A | N/A | N/A |
| Bioventus Inc. (BVS)vs › | $915.95M | 2.21x | 2.21x | 2.21x | 5.08x |
| Corvus Pharmaceuticals, Inc. (CRVS)vs › | $903.13M | N/A | N/A | N/A | N/A |
| Cullinan Therapeutics, Inc. (CGEM)vs › | $985.79M | N/A | N/A | N/A | N/A |
| Aktis Oncology, Inc. (AKTS)vs › | $989.05M | N/A | N/A | N/A | N/A |
| Monte Rosa Therapeutics, Inc. (GLUE)vs › | $867.60M | N/A | N/A | N/A | N/A |
| Apnimed, Inc. (APMD)vs › | $866.15M | N/A | N/A | N/A | N/A |
| Beta Bionics, Inc. (BBNX)vs › | $852.55M | N/A | N/A | N/A | N/A |
| Alumis Inc. (ALMS)vs › | $844.28M | N/A | N/A | N/A | N/A |
Interest Coverage
-30.9x
Debt/Equity
0.17
Current Ratio
9.18
Formula: Interest Coverage = EBIT / Interest Expense
Reference ranges:
Note: Interest coverage should be compared with historical interest expense, operating income, and industry capital structure.
Interest Coverage = EBIT / Interest Expense
The interest coverage ratio measures operating earnings relative to interest expense.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | INTEREST COVERAGE RATIO |
|---|---|
| 2026-06-30 | -45.62x |
| 2026-03-31 | -47.80x |
| 2025-12-31 | -31.59x |
| 2025-09-30 | -30.51x |
| 2025-06-30 | -31.35x |
| 2025-03-31 | -30.16x |
| 2024-12-31 | -25.82x |
| 2024-09-30 | -18.75x |
| 2024-06-30 | -17.54x |
| 2024-03-31 | -17.54x |
| 2023-12-31 | -16.34x |
| 2023-09-30 | -13.47x |
| 2023-06-30 | -13.77x |
| 2023-03-31 | -13.77x |
